Reproducibility and flexibility of monoclonal antibody production with Nicotiana benthamiana

Reproducibility and flexibility of monoclonal antibody production with Nicotiana benthamiana

The ongoing SARS-CoV-2 coronavirus pandemic of 2020–2021 underscores the need for manufacturing platforms that can rapidly produce monoclonal antibody (mAb) therapies. As reported here, a platform based on Nicotiana benthamiana produced mAb therapeutics with high batch-to-batch reproducibility and f...

Full description

Bibliographic Details
Main Authors: Kelsi Swope, Josh Morton, Gregory P. Pogue, Leigh Burden, Nicholas Partain, Steve Hume, John Shepherd, Carrie A. Simpson, Miles B. Brennan, Thomas C. Furman, Sheila Kingrey-Gebe, Theresa Martinez, Jim McDonough, Michael H. Pauly, Kevin J. Whaley, Larry Zeitlin, Barry Bratcher, Hugh Haydon
Format: Article
Language:English
Published: Taylor & Francis Group 2022-12-01
Series:mAbs
Subjects:
plant made pharmaceuticals
monoclonal antibody
nicotiana benthamiana
biologic
Online Access:http://dx.doi.org/10.1080/19420862.2021.2013594

Internet

http://dx.doi.org/10.1080/19420862.2021.2013594

Similar Items